Paresh Vyas

Q: What Schools Are Affiliated With Paresh Vyas

Paresh Vyas is affiliated with the following schools: University of California, Berkeley, University of Oxford, Stanford University, Harvard University

Paresh Vyas's AcademicInfluence.com Rankings

Paresh Vyas

Computer Science

#8344

World Rank

#8771

Historical Rank

Computational Linguistics

#1840

World Rank

#1859

Historical Rank

Machine Learning

#3396

World Rank

#3437

Historical Rank

Artificial Intelligence

#3694

World Rank

#3747

Historical Rank

computer-science Degrees

Download Badge

Computer Science

Paresh Vyas's Degrees

PhD Computer Science Stanford University
Masters Computer Science University of California, Berkeley
Bachelors Computer Science University of California, Berkeley

Similar Degrees You Can Earn

Why Is Paresh Vyas Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Paresh Vyas's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Clinical and biological implications of driver mutations in myelodysplastic syndromes. (2013) (1493)
Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. (2011) (1090)
Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. (2017) (1021)
Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party. (2018) (689)
Pathology and genetics: Tumours of haematopoietic and lymphoid tissues (2001) (672)
Clonal Evolution of Preleukemic Hematopoietic Stem Cells Precedes Human Acute Myeloid Leukemia (2012) (656)
Coexistence of LMPP-like and GMP-like leukemia stem cells in acute myeloid leukemia. (2011) (572)
Assessment of Minimal Residual Disease in Standard-Risk AML. (2016) (543)
Patterns of somatic structural variation in human cancer genomes (2020) (377)
Origins and functional consequences of somatic mitochondrial DNA mutations in human cancer (2014) (358)
Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML). (2012) (343)
Factors influencing success of clinical genome sequencing across a broad spectrum of disorders (2015) (319)
Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia. (2010) (313)
Haploinsufficiency of GATA-2 perturbs adult hematopoietic stem-cell homeostasis. (2005) (299)
Single-cell transcriptomics uncovers distinct molecular signatures of stem cells in chronic myeloid leukemia (2017) (284)
Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response. (2017) (282)
Myelodysplastic syndromes are propagated by rare and distinct human cancer stem cells in vivo. (2014) (277)
GATA‐1 forms distinct activating and repressive complexes in erythroid cells (2005) (265)
International Consensus Classification of Myeloid Neoplasms and Acute Leukemia: Integrating Morphological, Clinical, and Genomic Data. (2022) (249)
Persistent malignant stem cells in del(5q) myelodysplasia in remission. (2010) (245)
Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes. (2020) (238)
Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia (2015) (234)
Natural history of GATA1 mutations in Down syndrome. (2004) (233)
Acute myeloid leukemia creates an arginase-dependent immunosuppressive microenvironment. (2013) (223)
Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib. (2019) (221)
Standardization of flow cytometry in myelodysplastic syndromes: report from the first European LeukemiaNet working conference on flow cytometry in myelodysplastic syndromes (2009) (205)
Consequences of GATA-1 Deficiency in Megakaryocytes and Platelets (1999) (198)
Combining gene mutation with gene expression data improves outcome prediction in myelodysplastic syndromes (2015) (197)
Comprehensive molecular characterization of mitochondrial genomes in human cancers (2017) (197)
Identification of distinct molecular phenotypes in acute megakaryoblastic leukemia by gene expression profiling. (2006) (186)
Genome-wide identification of TAL1's functional targets: insights into its mechanisms of action in primary erythroid cells. (2010) (181)
Consequences of GATA-1 deficiency in megakaryocytes and platelets. (1999) (174)
Recent insights into the mechanisms of myeloid leukemogenesis in Down syndrome. (2004) (162)
ETO-2 Associates with SCL in Erythroid Cells and Megakaryocytes and Provides Repressor Functions in Erythropoiesis (2005) (158)
Cis-acting sequences regulating expression of the human α-globin cluster lie within constitutively open chromatin (1992) (155)
Different sequence requirements for expression in erythroid and megakaryocytic cells within a regulatory element upstream of the GATA-1 gene. (1999) (149)
The First-in-Class Anti-CD47 Antibody Magrolimab (5F9) in Combination with Azacitidine Is Effective in MDS and AML Patients: Ongoing Phase 1b Results (2019) (149)
Tolerability and Clinical Activity of Post-Transplantation Azacitidine in Patients Allografted for Acute Myeloid Leukemia Treated on the RICAZA Trial (2016) (147)
Impact of spliceosome mutations on RNA splicing in myelodysplasia: dysregulated genes/pathways and clinical associations. (2018) (146)
Abnormalities in the myeloid progenitor compartment in Down syndrome fetal liver precede acquisition of GATA1 mutations. (2008) (145)
TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups (2019) (141)
Perturbation of fetal liver hematopoietic stem and progenitor cell development by trisomy 21 (2012) (136)
Multicenter validation of a reproducible flow cytometric score for the diagnosis of low-grade myelodysplastic syndromes: results of a European LeukemiaNET study (2012) (136)
Evidence for reduced B-cell progenitors in early (low-risk) myelodysplastic syndrome. (2005) (134)
GATA1-mutant clones are frequent and often unsuspected in babies with Down syndrome: identification of a population at risk of leukemia. (2013) (130)
Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib (2018) (129)
Mice lacking transcription factor NF-E2 provide in vivo validation of the proplatelet model of thrombocytopoiesis and show a platelet production defect that is intrinsic to megakaryocytes. (1998) (125)
Azacitidine fails to eradicate leukemic stem/progenitor cell populations in patients with acute myeloid leukemia and myelodysplasia (2013) (125)
Single-cell analysis reveals the continuum of human lympho-myeloid progenitor cells (2017) (121)
Longitudinal monitoring of immune reconstitution by CDR3 size spectratyping after T-cell-depleted allogeneic bone marrow transplant and the effect of donor lymphocyte infusions on T-cell repertoire. (2000) (114)
Acute megakaryoblastic leukaemia (AMKL) and transient myeloproliferative disorder (TMD) in Down syndrome: a multi‐step model of myeloid leukaemogenesis (2009) (109)
Enasidenib in mutant IDH 2 relapsed or refractory acute myeloid leukemia (2017) (107)
Genetically distinct leukemic stem cells in human CD34− acute myeloid leukemia are arrested at a hemopoietic precursor-like stage (2016) (101)
SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS (2020) (98)
Acute leukemias in children with Down syndrome. (2008) (98)
Analysis of GATA1 mutations in Down syndrome transient myeloproliferative disorder and myeloid leukemia. (2011) (97)
Transient Abnormal Myelopoiesis and AML in Down Syndrome: an Update (2016) (96)
Contrasting effects of alpha and beta globin regulatory elements on chromatin structure may be related to their different chromosomal environments. (1995) (95)
Somatic Mutations in MDS Patients Are Associated with Clinical Features and Predict Prognosis Independent of the IPSS-R: Analysis of Combined Datasets from the International Working Group for Prognosis in MDS-Molecular Committee (2015) (95)
GATA-2 regulates granulocyte-macrophage progenitor cell function. (2008) (94)
Quantifying and Imaging NY-ESO-1/LAGE-1-Derived Epitopes on Tumor Cells Using High Affinity T Cell Receptors (2006) (89)
Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional care (2018) (86)
Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid Leukemia (2020) (85)
Assessment of minimal residual disease in acute myeloid leukemia (2010) (80)
GATA1-Mediated Megakaryocyte Differentiation and Growth Control Can Be Uncoupled and Mapped to Different Domains in GATA1 (2005) (80)
Editing an α-globin enhancer in primary human hematopoietic stem cells as a treatment for β-thalassemia (2017) (77)
DOT1L inhibition reveals a distinct subset of enhancers dependent on H3K79 methylation (2018) (77)
Guidelines for the diagnosis and management of adult myelodysplastic syndromes (2014) (76)
Mice Lacking Transcription Factor NF-E2 Provide In Vivo Validation of the Proplatelet Model of Thrombocytopoiesis and Show a Platelet Production Defect That Is Intrinsic to Megakaryocytes (1998) (74)
Factors predicting long-term survival after T-cell depleted reduced intensity allogeneic stem cell transplantation for acute myeloid leukemia (2010) (72)
Haematology of Down syndrome (2007) (70)
Structure of the leukemia oncogene LMO2: implications for the assembly of a hematopoietic transcription factor complex. (2011) (69)
Characterization of megakaryocyte GATA1-interacting proteins: the corepressor ETO2 and GATA1 interact to regulate terminal megakaryocyte maturation. (2008) (69)
Outcome of Azacitidine Therapy in Acute Myeloid Leukemia Is not Improved by Concurrent Vorinostat Therapy but Is Predicted by a Diagnostic Molecular Signature (2017) (68)
SF3B1-mutant myelodysplastic syndrome as a distinct disease subtype - A Proposal of the International Working Group for the Prognosis of Myelodysplastic Syndromes (IWG-PM). (2020) (68)
Differences in the chromatin structure and cis-element organization of the human and mouse GATA1 loci: implications for cis-element identification. (2004) (67)
Molecular insights into Down syndrome-associated leukemia (2007) (66)
Generation of bivalent chromatin domains during cell fate decisions (2011) (65)
New directions for emerging therapies in acute myeloid leukemia: the next chapter (2020) (65)
Myeloid leukemia in children 4 years or older with Down syndrome often lacks GATA1 mutation and cytogenetics and risk of relapse are more akin to sporadic AML (2008) (65)
Defective nuclear localization of Hsp70 is associated with dyserythropoiesis and GATA-1 cleavage in myelodysplastic syndromes. (2012) (64)
Differential use of SCL/TAL-1 DNA-binding domain in developmental hematopoiesis. (2008) (61)
Uncoupling VEGFA Functions in Arteriogenesis and Hematopoietic Stem Cell Specification (2013) (61)
Conservation of position and sequence of a novel, widely expressed gene containing the major human alpha-globin regulatory element. (1995) (61)
Mechanisms of Progression of Myeloid Preleukemia to Transformed Myeloid Leukemia in Children with Down Syndrome. (2019) (60)
Cardiac iron overload in transfusion‐dependent patients with myelodysplastic syndromes (2011) (59)
Tolerability and efficacy of the first-in-class anti-CD47 antibody magrolimab combined with azacitidine in MDS and AML patients: Phase Ib results. (2020) (59)
An operational definition of primary refractory acute myeloid leukemia allowing early identification of patients who may benefit from allogeneic stem cell transplantation (2016) (58)
The effects of monoclonal anti‐CD47 on RBCs, compatibility testing, and transfusion requirements in refractory acute myeloid leukemia (2019) (58)
Analysis of the human alpha-globin gene cluster in transgenic mice. (1993) (56)
Structure of the human 3-methyladenine DNA glycosylase gene and localization close to the 16p telomere. (1993) (55)
Structural Basis for LMO2-Driven Recruitment of the SCL:E47bHLH Heterodimer to Hematopoietic-Specific Transcriptional Targets (2013) (55)
Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts (2020) (55)
Biology and management of transient abnormal myelopoiesis (TAM) in children with Down syndrome. (2012) (54)
The Medalist Trial: Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Luspatercept to Treat Anemia in Patients with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS) Who Require Red Blood Cell (RBC) Transfusions (2018) (53)
Selective impairment of platelet activation to collagen in the absence of GATA1. (2005) (52)
Mutational analysis of disease relapse in patients allografted for acute myeloid leukemia. (2016) (52)
Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial. (2021) (52)
Augmented Reduced-Intensity Regimen Does Not Improve Postallogeneic Transplant Outcomes in Acute Myeloid Leukemia (2020) (50)
Discovery of a CD10 negative B-progenitor in human fetal life identifies unique ontogeny-related developmental programs. (2019) (50)
Inositol polyphosphate 4-phosphatase type I regulates cell growth downstream of transcription factor GATA-1. (2000) (50)
The first-in-class anti-CD47 antibody Hu5F9-G4 is active and well tolerated alone or with azacitidine in AML and MDS patients: Initial phase 1b results. (2019) (49)
Heterogeneity of human lympho-myeloid progenitors at the single cell level (2017) (49)
GATA-1 forms distinct activating and repressive complexes in erythroid cells (2004) (49)
Phase Ib/II study of the IDH1-mutant inhibitor ivosidenib with the BCL2 inhibitor venetoclax +/- azacitidine in IDH1-mutated hematologic malignancies. (2020) (48)
The U2AF1S34F mutation induces lineage-specific splicing alterations in myelodysplastic syndromes (2017) (47)
Impact of isolated germline JAK2V617I mutation on human hematopoiesis. (2013) (46)
Allogeneic hematopoietic cell transplantation for acute myeloid leukemia. (2015) (46)
Mrvil, a common MRV integration site in BXH2 myeloid leukemias, encodes a protein with homology to a lymphoid-restricted membrane protein Jaw1 (1999) (46)
The Graft-Versus-Leukemia Effect in AML (2019) (45)
Decoding Hematopoietic Specificity in the Helix-Loop-Helix Domain of the Transcription Factor SCL/Tal-1 (2004) (44)
SCL-mediated regulation of the cell-cycle regulator p21 is critical for murine megakaryopoiesis. (2011) (43)
FLT3-ITDs Instruct a Myeloid Differentiation and Transformation Bias in Lymphomyeloid Multipotent Progenitors (2013) (43)
Acute leukemias in children with Down syndrome. (2010) (42)
GATA1 mutation and trisomy 21 are required only in haematopoietic cells for development of transient myeloproliferative disorder (2005) (42)
Enasidenib Plus Azacitidine Significantly Improves Complete Remission and Overall Response Compared with Azacitidine Alone in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) with Isocitrate Dehydrogenase 2 (IDH2) Mutations: Interim Phase II Results from an Ongoing, Randomized Study (2019) (42)
Sex differences in oncogenic mutational processes (2019) (41)
Mutant Isocitrate Dehydrogenase (mIDH) Inhibitors, Enasidenib or Ivosidenib, in Combination with Azacitidine (AZA): Preliminary Results of a Phase 1b/2 Study in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) (2017) (39)
Guidelines for the investigation and management of Transient Leukaemia of Down Syndrome (2018) (39)
The α‐Thalassemias (1990) (39)
Analysis of JAK3, JAK2, and C-MPL mutations in transient myeloproliferative disorder and myeloid leukemia of Down syndrome blasts in children with Down syndrome. (2007) (39)
The U2AF1S34F mutation induces lineage-specific splicing alterations in myelodysplastic syndromes. (2017) (38)
Mutant IDH (mIDH) inhibitors, ivosidenib or enasidenib, with azacitidine (AZA) in patients with acute myeloid leukemia (AML). (2018) (34)
High expression of HMGA2 independently predicts poor clinical outcomes in acute myeloid leukemia (2018) (34)
Multiple Cereblon genetic changes associate with acquired resistance to Lenalidomide or Pomalidomide in Multiple Myeloma. (2020) (33)
Deletion of the major GATA1 enhancer HS 1 does not affect eosinophil GATA1 expression and eosinophil differentiation. (2004) (33)
GATA1s induces hyperproliferation of eosinophil precursors in Down syndrome transient leukemia (2013) (32)
Phase III, Randomized, Placebo-Controlled Trial of CC-486 (Oral Azacitidine) in Patients With Lower-Risk Myelodysplastic Syndromes (2021) (32)
Severe TMD/AMKL with GATA1 mutation in a stillborn fetus with Down syndrome (2007) (29)
SF3B1 mutations induce R-loop accumulation and DNA damage in MDS and leukemia cells with therapeutic implications (2020) (29)
Multiple cereblon genetic changes are associated with acquired resistance to lenalidomide or pomalidomide in multiple myeloma. (2021) (29)
Reduced CD38 expression on CD34+ cells as a diagnostic test in myelodysplastic syndromes (2009) (28)
Prenatal therapy in transient abnormal myelopoiesis: a systematic review (2015) (27)
Down syndrome preleukemia and leukemia. (2015) (27)
Role of upstream DNase I hypersensitive sites in the regulation of human alpha globin gene expression. (1993) (26)
Down myeloid disorders: a paradigm for childhood preleukaemia and leukaemia and insights into normal megakaryopoiesis. (2006) (26)
The 44th Annual Meeting of the European Society for Blood and Marrow Transplantation: Physicians Poster Sessions (2018) (26)
Minimizing risk of hypomethylating agent failure in patients with higher-risk MDS and practical management recommendations. (2014) (26)
SCL/TAL1 cooperates with Polycomb RYBP-PRC1 to suppress alternative lineages in blood-fated cells (2018) (26)
Episomal amplification of NUP214-ABL1 fusion gene in B-cell acute lymphoblastic leukemia. (2012) (25)
H3K79me2/3 controls enhancer–promoter interactions and activation of the pan-cancer stem cell marker PROM1/CD133 in MLL-AF4 leukemia cells (2020) (25)
Effect of enasidenib (ENA) plus azacitidine (AZA) on complete remission and overall response versus AZA monotherapy in mutant-IDH2 (mIDH2) newly diagnosed acute myeloid leukemia (ND-AML). (2020) (24)
Development of Real-Time Quantitative Polymerase Chain Reaction Assays to Track Treatment Response in Retinoid Resistant Acute Promyelocytic Leukemia (2011) (24)
Prognostic value of monitoring a candidate immunophenotypic leukemic stem/progenitor cell population in patients allografted for acute myeloid leukemia (2014) (23)
Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples (2020) (22)
Results of the Phase 1 Trial of RG7112, a Small-Molecule MDM2 Antagonist, in Acute Leukemia (2012) (22)
Human erythroleukemia genetics and transcriptomes identify master transcription factors as functional disease drivers. (2020) (22)
Linkage and mutational analysis of the CDAN1 gene reveals genetic heterogeneity in congenital dyserythropoietic anemia type I. (2006) (21)
A phase Ib/II study of ivosidenib with venetoclax +/- azacitidine in IDH1-mutated myeloid malignancies. (2021) (21)
The impact of trisomy 21 on foetal haematopoiesis. (2013) (21)
Molecular targeting of cancer stem cells. (2009) (20)
Alternative agents to prophylactic platelet transfusion for preventing bleeding in people with thrombocytopenia due to chronic bone marrow failure: a meta-analysis and systematic review. (2016) (20)
AML-196: The First-in-Class Anti-CD47 Antibody Magrolimab in Combination with Azacitidine Is Well Tolerated and Effective in AML Patients: Phase 1b Results (2021) (19)
Comparison of a restrictive versus liberal red cell transfusion policy for patients with myelodysplasia, aplastic anaemia, and other congenital bone marrow failure disorders. (2015) (19)
GATA1 and cooperating mutations in myeloid leukaemia of Down syndrome (2019) (19)
Mutant IDH1 inhibitor ivosidenib (IVO; AG-120) in combination with azacitidine (AZA) for newly diagnosed acute myeloid leukemia (ND AML). (2019) (18)
The genome-wide impact of trisomy 21 on DNA methylation and its implications for hematopoiesis (2021) (17)
Distinct factors determine the kinetics of disease relapse in adults transplanted for acute myeloid leukaemia (2018) (17)
Characterization of a Megakaryocyte-specific Enhancer of the Key Hemopoietic Transcription Factor GATA1* (2006) (16)
Measurement of utility values in the UK for health states related to immune thrombocytopenic purpura (2010) (15)
Tolerability and efficacy of the first-in-class anti-CD47 antibody magrolimab combined with azacitidine in frontline TP53m AML patients: Phase 1b results. (2022) (15)
Magrolimab + azacitidine versus azacitidine + placebo in untreated higher risk (HR) myelodysplastic syndrome (MDS): The phase 3, randomized, ENHANCE study. (2021) (15)
Lineage-specific combinatorial action of enhancers regulates mouse erythroid Gata1 expression. (2010) (15)
GATA1 mutation analysis demonstrates two distinct primary leukemias in a child with down syndrome; implications for leukemogenesis. (2005) (15)
Regulation of human embryonic globin genes zeta 2 and epsilon in stably transformed mouse erythroleukemia cells. (1992) (14)
A Recurrent Activating Missense Mutation in Waldenström Macroglobulinemia Affects the DNA Binding of the ETS Transcription Factor SPI1 and Enhances Proliferation. (2019) (14)
A Phase 1b Study of Glasdegib in Combination with Azacitidine in Patients with Untreated Higher-Risk Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia (2019) (14)
Heterogeneous leukemia stem cells in myeloid blast phase chronic myeloid leukemia. (2016) (13)
Chromatin accessibility governs the differential response of cancer and T cells to arginine starvation (2021) (13)
Mutant IDH1 Inhibitor Ivosidenib (IVO; AG-120) in Combination with Azacitidine (AZA) for Newly Diagnosed Acute Myeloid Leukemia (ND AML) (2019) (13)
High Rate of IDH1 Mutation Clearance and Measurable Residual Disease Negativity in Patients with IDH1-Mutant Newly Diagnosed Acute Myeloid Leukemia Treated with Ivosidenib (AG-120) and Azacitidine (2019) (12)
C/EBPα and GATA-2 Mutations Induce Bilineage Acute Erythroid Leukemia through Transformation of a Neomorphic Neutrophil-Erythroid Progenitor (2020) (12)
Clinical Benefit of Glasdegib in Combination with Azacitidine or Low-Dose Cytarabine in Patients with Acute Myeloid Leukemia (2019) (12)
An immunophenotypic pre‐treatment predictor for poor response to induction chemotherapy in older acute myeloid leukaemia patients: blood frequency of CD34+ CD38low blasts (2015) (11)
c‐Myb and GATA‐1 alternate dominant roles during megakaryocyte differentiation (2011) (11)
TP53-Mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia: Biology, Current Therapy, and Future Directions (2022) (11)
Somatic Mutation of SF3B1, a Gene Encoding a Core Component of RNA Splicing Machinery, in Myelodysplasia with Ring Sideroblasts (2011) (10)
Clinical Activity of CC-90009, a Cereblon E3 Ligase Modulator and First-in-Class GSPT1 Degrader, As a Single Agent in Patients with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML): First Results from a Phase I Dose-Finding Study (2019) (10)
Alternative agents versus prophylactic platelet transfusion for preventing bleeding in patients with thrombocytopenia due to chronic bone marrow failure: a network meta-analysis and systematic review. (2016) (10)
RBC-Specific CD47 Pruning Confers Protection and Underlies the Transient Anemia in Patients Treated with Anti-CD47 Antibody 5F9 (2018) (10)
The impact of trisomy 21 on early human hematopoiesis (2013) (10)
5 ' Azacitidine in Combination with Valproic Acid Induces Complete Remissions in Patients with Advanced Acute Myeloid Leukaemia but Does Not Eradicate Clonal Leukaemic Stem/Progenitor Cells. (2008) (10)
Normal Hematopoietic Progenitor Subsets Have Distinct Reactive Oxygen Species, BCL2 and Cell-Cycle Profiles That Are Decoupled from Maturation in Acute Myeloid Leukemia (2016) (10)
Marked down‐regulation of nucleophosmin‐1 is associated with advanced del(5q) myelodysplastic syndrome (2011) (9)
Applicability and reproducibility of acute myeloid leukaemia stem cell assessment in a multi‐centre setting (2020) (9)
PF291 A PHASE 1B/2 CLINICAL STUDY OF TARGETED IDH1 INHIBITION WITH IVOSIDENIB, IN COMBINATION WITH THE BCL-2 INHIBITOR VENETOCLAX, FOR PATIENTS WITH IDH1-MUTATED (MIDH1) MYELOID MALIGNANCIES (2019) (9)
Erratum: The U2AF1S34F mutation induces lineage-specific splicing alterations in myelodysplastic syndromes (The Journal of clinical investigation (2017) 127 6 (2206-2221) PII: 96202) (2017) (8)
Integrating clinical features with genetic factors enhances survival prediction for adults with acute myeloid leukemia. (2020) (8)
The targeted histone deacetylase inhibitor tefinostat (CHR-2845) shows selective in vitro efficacy in monocytoid-lineage leukaemias (2016) (8)
Evidence of genetic heterogeneity in congenital dyserythropoietic anaemia type I (2006) (8)
Identification of two DNA methylation subtypes of Waldenström's macroglobulinemia with plasma and memory B cell features. (2020) (8)
Molecular Detection of Minimal Residual Disease Provides the Most Powerful Independent Prognostic Factor Irrespective of Clonal Architecture in Nucleophosmin (NPM1) Mutant Acute Myeloid Leukemia (2014) (8)
Clever leukemic stem cells branch out. (2011) (8)
Lenalidomide monotherapy and in combination with cytarabine, daunorubicin and etoposide for high-risk myelodysplasia and acute myeloid leukaemia with chromosome 5 abnormalities☆ (2013) (8)
A Phase 3, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination with Azacitidine in Previously Untreated Patients with TP53-Mutant Acute Myeloid Leukemia (2021) (8)
AML-348 A Phase Ib/II Study of Ivosidenib With Venetoclax +/- Azacitidine in IDH1-Mutated Hematologic Malignancies. (2022) (8)
Combined inhibition of XIAP and BCL2 drives maximal therapeutic efficacy in genetically diverse aggressive acute myeloid leukemia (2021) (8)
Targeting HIF function: the debate continues. (2014) (7)
Absence of mutations in the key megakaryocyte transcriptional regulator FOG‐1 in patients with idiopathic myelofibrosis (2004) (7)
Outcomes for Patients with Late-Stage Mutant-IDH2 (m IDH2) Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) Treated with Enasidenib Vs Other Lower-Intensity Therapies in the Randomized, Phase 3 IDHentify Trial (2021) (7)
From genomics to targeted treatment in haematological malignancies: a focus on acute myeloid leukaemia (2018) (6)
O-001 Clinical and biological implications of gene mutations in MDS (2013) (6)
The interaction of alpha thalassaemia and sickle cell–beta° thalassaemia (1988) (6)
Erratum: Mechanisms of Progression of Myeloid Preleukemia to Transformed Myeloid Leukemia in Children with Down Syndrome (Cancer Cell (2019) 36(2) (123–138.e10), (S1535610819302983), (10.1016/j.ccell.2019.06.007)) (2019) (6)
Clonal Heterogeneity in Differentiation Response and Resistance to the IDH2 Inhibitor Enasidenib in Acute Myeloid Leukemia (2017) (5)
Outcomes of Relapsed/Refractory Patients with IDH1/2 Mutated AML Treated with Non-Targeted Therapy: Results from the NCRI AML Trials (2018) (5)
Oncogenic Gata1 causes stage-specific megakaryocyte differentiation delay (2019) (5)
Reprint of: Allogeneic hematopoietic cell transplantation for acute myeloid leukemia. (2015) (5)
The Inflammasome: More Than a Protective Innate Immune Mechanism. (2019) (5)
MOLECULAR PREDICTORS OF RESPONSE TO AZACITIDINE THERAPY: THE RESULTS OF THE UK TRIALS ACCELERATION PROGRAMME RAVVA STUDY (2017) (4)
A myelodysplastic syndrome associated with a clonal GATA1 mutation (2008) (4)
Mechanisms of Progression of Myeloid Preleukemia to Transformed Myeloid Leukemia in Children with Down Syndrome. (2019) (4)
Development and Evaluation of the Clinical Utility of a Next Generation Sequencing (NGS) Tool for Myeloid Disorders (2014) (4)
Broad Activity for the Pivekimab Sunirine (PVEK, IMGN632), Azacitidine, and Venetoclax Triplet in High-Risk Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) (2022) (4)
Supplementary file 1. (2015) (4)
Supplementary file 3. (2014) (4)
A phase 1b study of glasdegib + azacitidine in patients with untreated acute myeloid leukemia and higher-risk myelodysplastic syndromes (2022) (4)
Pharmacodynamic Responses to CC-90009, a Novel Cereblon E3 Ligase Modulator, in a Phase I Dose-Escalation Study in Relapsed or Refractory Acute Myeloid Leukemia (R/R AML) (2019) (3)
Characterization of the telomeric region of human chromosome 16p (1993) (3)
Trisomy 21 expands the megakaryocyte-erythroid progenitor compartment in human fetal liver-implications for down syndrome AMKL. (2006) (3)
Enasidenib vs conventional care in mutant-IDH2 relapsed/refractory acute myeloidleukemia: a randomized, phase 3 trial. (2022) (3)
Sensitive, Rapid Diagnostic Test For Transient Abnormal Myelopoiesis and Myeloid Leukemia of Down Syndrome. (2020) (3)
Vorinostat Does Not Improve Outcome in Patients with Acute Myeloid Leukemia and High Risk Myelodysplasia Treated with Azacitidine: Results of the UK Trials Acceleration Programme Ravva Trial (2016) (3)
High Throughput Targeted Gene Sequencing in 738 Myelodysplastic Syndromes Patients Reveals Novel Oncogenic Genes, Rare Driver Mutations and Complex Molecular Signatures with Potential Impact for Patient Diagnosis and Prognosis in the Clinic (2012) (3)
Azacitidine (AZA) Prolongs Overall Survival in Older Patients with Acute Myeloid Leukemia (AML) with Poor Prognostic Karyotypes Compared with Conventional Care Regimens (CCR) (2016) (3)
Scabies Infestation following Autologous Bone Marrow Transplantation. (1990) (3)
A multicenter comparative acute myeloid leukemia study: can we explain the differences in the outcomes in resource-constrained settings? (2020) (3)
A phenotypic screen identifies a compound series that induces differentiation of acute myeloid leukemia cells in vitro and shows anti-tumour effects in vivo (2020) (3)
Ivosidenib Improves Overall Survival Relative to Standard Therapies in Relapsed or Refractory Mutant IDH1 AML: Results from Matched Comparisons to Historical Controls (2020) (3)
An Operational Definition of Primary Refractory Acute Myeloid Leukaemia Which Allows Early Identification of Patients for Whom Allogeneic Stem Cell Transplantation Represents the Only Curative Therapy (2015) (3)
A shared somatic translocation involving CUX1 in monozygotic twins as an early driver of AMKL in Down syndrome (2020) (3)
The interaction of alpha thalassaemia and sickle cell-beta zero thalassaemia. (1988) (3)
Disease Models & Mechanisms announces a new Editor-in-Chief (2020) (3)
Glasdegib in combination with azacitidine (AZA) in patients (pts) with untreated higher-risk myelodysplastic syndromes (MDS), acute myeloid leukemia (AML) and chronic myelomonocytic leukemia (CMML): Effects on marrow recovery and transfusion independence. (2020) (3)
Methotrexate dose delivery is more important than ciclosporin level in graft-versus-host disease prophylaxis following T-replete reduced-intensity sibling allogeneic stem cell transplant (2011) (3)
Cellular basis of hematopoiesis and stem cell transplantation (2016) (2)
Analysis of factors affecting outcome in recipients of bone marrow transplantation for myelodysplasia; a single centre's experience over a nine year period (2010) (2)
Selection and management of older patients with acute myeloid leukemia treated with glasdegib plus low-dose cytarabine: expert panel review (2020) (2)
IDENTIFICATION OF ABERRANTLY SPLICED GENES AND DEREGULATED PATHWAYS/GENE ONTOLOGY THEMES IN MYELODYSPLASTIC SYNDROME PATIENTS WITH SPLICING FACTOR GENE MUTATIONS (2017) (2)
Integrative multi-omics identifies high risk multiple myeloma subgroup associated with significant DNA loss and dysregulated DNA repair and cell cycle pathways (2021) (2)
Germline activating JAK2-mutation in a family with hereditary thrombocytosis (2012) (2)
A novel tubulin binding molecule drives differentiation of acute myeloid leukaemia cells (2021) (2)
Results of a Phase 2 Trial of the Monocyte-Targeted Histone Deacetylase Inhibitor Tefinostat (CHR-2845) in Chronic Myelomonocytic Leukemia (CMML) — the UK Monocle Study (2018) (2)
G371 Defining transient abnormal myelopoiesis (TAM) and silent tam in neonates with down syndrome (2016) (2)
Receptors Tumor Cells Using High Affinity T Cell NY-ESO-1 / LAGE-1-Derived Epitopes on Quantifying and Imaging (2006) (2)
A NOVEL MODEL OF HUMAN LYMPHO-MYELOID PROGENITOR HIERARCHY BASED ON SINGLE CELL FUNCTIONAL AND TRANSCRIPTIONAL ANALYSIS (2017) (2)
Supplementary file 2. (2014) (2)
Characterization of the hemopoietic defect in early stages of the myelodysplastic syndromes. (2006) (2)
Sowing the seeds of leukemia before birth (2021) (2)
Association Between Gene Expression Profiles and Commonly Mutated Genes In The Hematopoietic Stem Cells Of Patients With Myelodysplastic Syndromes (2013) (2)
Comparison of a restrictive versus liberal red cell transfusion policy for patients with myelodysplasia, aplastic anaemia, and other congenital bone marrow failure disorders. (2015) (2)
50 The identification of novel somatic mutations in MDS by whole exome sequencing (2011) (2)
Transient abnormal myelopoiesis without constitutional Down syndrome (2020) (1)
LLM Abstracts, AJH, V96 S1 (2021) (1)
BCL-2 Inhibitor and Conventional Chemotherapy Combinations for Acute Myeloid Leukemia: Shifting From the Unfit to the Fit Patient With AML. (2020) (1)
NEXT GENERATION SEQUENCING TECHNIQUES REVEAL MOLECULAR MECHANISMS OF MYB REGULATION AND FUNCTION IN MLL-AF9 LEUKEMIA (2017) (1)
Overall survival by IDH2 mutant allele (R140 or R172) in patients with late-stage mutant-IDH2 relapsed or refractory acute myeloid leukemia treated with enasidenib or conventional care regimens in the phase 3 IDHENTIFY trial. (2022) (1)
Azacitidine Induces Expansion of Regulatory T Cells and Tumour Specific CD8+T Lymphocytes After Allogeneic Stem Cell Transplantation: A Strategy for Epigenetic Manipulation of a Graft-Versus-Leukemia Response (2011) (1)
Characterization of a Megakaryocyte-Specific Enhancer of the Key Hemopoietic Transcription Factor GATA1. (2005) (1)
Identification of Prognostic Markers by Gene Expression Profiling In Myelodysplastic Syndrome Hematopoietic Stem Cells (2010) (1)
Loss of COP9 Signalosome Gene-Containing 2q Region Is Associated with Lenalidomide and Pomalidomide Resistance in Myeloma Patients (2021) (1)
Analysis of arginine metabolism in acute myeloid leukaemia to provide insights into tumour immune escape strategies (2017) (1)
Residual Disease Detection by Flow Cytometry Predicts Risk of Relapse and Overall Survival in Patients with Acute Myeloid Leukemia Following Reduced Intensity- and Myeloablative-Allogeneic Hematopoietic Cell Transplantation (2012) (1)
THE STRUCTURE AND FUNCTION OF CIS-ACTING REGULATORY SEQUENCES UPSTREAM OF THE HUMAN ALPHA-GLOBIN GENE-COMPLEX (1991) (1)
Germline Activating JAK2 V617I Mutation in a Family with Hereditary Thrombocytosis (2011) (1)
Reduced CD38 Expression on CD34+Cells as a Diagnostic Test in Myelodysplastic Syndromes. (2008) (1)
Trilineage Perturbation of Hematopoiesis In Neonates with Down Syndrome (2010) (1)
Loss Of COP9-Signalosome Genes At 2q37 Is Associated With IMiD Agent Resistance In Multiple Myeloma. (2022) (1)
Transcriptional regulation of GATA1 (2007) (1)
IDENTIFICATION OF ABERRANT SPLICING EVENTS IN MYELODYSPLASTIC SYNDROME PATIENTS WITH SPLICING FACTOR GENE MUTATIONS (2017) (1)
PLATELET DYSFUNCTION AND MDS FEATURES DUE TO NOVEL SOMATIC GATA1 MUTATION (2010) (1)
Identification and Age-dependent Increase of Platelet Biased Human Hematopoietic Stem Cells (2022) (1)
Quantitation of Leukemic Stem Cell Populations Predicts Clinical Outcome in Acute Myeloid Leukaemia (2011) (1)
Natural history of GATA1mutations in Down syndrome (2016) (1)
Mutational analysis of the CDAN1 gene in familial and sporadic congenital dyserythropoietic anaemia type 1 (2003) (1)
PS1023 MUTANT IDH1 INHIBITOR IVOSIDENIB (AG-120) IN COMBINATION WITH AZACITIDINE FOR NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (2019) (1)
Modelling the progression of a preleukemic stage to overt leukemia in children with Down syndrome (2018) (1)
Leukemia Stem Cell Potential of Different Progenitor Subpopulations in Myeloid Blast Phase CML (2014) (1)
Oncogenic Drivers and Development. (2019) (1)
Induction of a CD8+T Cell Response to Tumor Antigens Is Associated with Improved Survival in Patients Transplanted for Acute Myeloid Leukemia (2014) (1)
COMBINED ANALYSES OF ROS, CELL CYCLE AND IMMUNOPHENOTYPE SHOWS THAT NORMAL HEMATOPOIETIC PROGENITOR SUBSETS HAVE A DIFFERENTIAL ROS PROFILE THAT IS LOST IN ACUTE MYELOID LEUKEMIA (2013) (1)
A Phase 2, Open-Label, Multiarm, Multicenter Study to Evaluate Magrolimab Combined with Antileukemia Therapies for First-Line, Relapsed/Refractory, or Maintenance Treatment of Acute Myeloid Leukemia (2021) (1)
Poorer Clinical Outcomes for Black Patients with AML: A Wake-Up Call for Better Data and Greater Understanding of Cancer Outcomes in All Ethnic Groups. (2021) (1)
VEGFA Controls Haematopoietic Stem Cell Specification In a Dose Dependent, Isoform Specific Manner (2010) (1)
COMPARISON OF A RESTRICTIVE VERSUS LIBERAL RED BLOOD CELL TRANSFUSION POLICY IN MYELODYSPLASTIC SYNDROMES AND OTHER BONE MARROW FAILURE DISORDERS - A SYSTEMATIC REVIEW (2015) (1)
GATA1 Mutation In Transient Leukemia (TL) and Myeloid Leukemia of Down Syndrome (2010) (1)
177 UK experience of azacitidine therapy in patients with myelodysplastic syndromes (2011) (1)
GENOME WIDE DYSREGULATION OF GENE EXPRESSION BY TRISOMY 21 IN FETAL LIVER HAEMATOPOIETIC STEM AND PROGENITOR CELLS (2016) (1)
hematopoiesis Differential use of SCL / TAL-1 DNA-binding domain in developmental (2008) (1)
Characterization of Factors Determining the Kinetics of Disease Relapse after Allogeneic Stem Cell Transplantation (allo-SCT) or Chemotherapeutic Consolidation for Acute Myeloid Leukaemia (AML) in First CR: A Survey from HOVON-SAKK and the Acute Leukaemia Working Party of the EBMT (2016) (1)
Molecular Characterization of Clinical Response and Relapse in Patients with IDH1-Mutant Newly Diagnosed Acute Myeloid Leukemia Treated with Ivosidenib and Azacitidine (2020) (1)
Combination romidepsin and azacitidine therapy is well tolerated and clinically active in adults with high‐risk acute myeloid leukaemia ineligible for intensive chemotherapy (2021) (1)
Response: JAK mutations in Down syndrome-associated transient myeloproliferative disorder and acute megakaryocytic leukemia (2008) (1)
Single Cell Analysis of Acquired Pomalidomide-Resistance in Multiple Myeloma Cell Lines Reveals Distinct Subclonal Cereblon Mutations and Gene Expression Heterogeneity (2018) (1)
Haploinsufficiency of GAtA-2 effects adult stem cell homeostasis. (2003) (1)
VASCULAR AND PLATELET BLEEDING DISORDERS (2018) (1)
Supplementary File 4 (2014) (1)
CELLULAR BASIS OF HEMATOPOIESIS (2010) (1)
Repressed Chromatin Drives Leukaemogenesis in Mutant IDH2 Acute Myeloid Leukaemia Via Inhibition of Granulocyte Differentiation and Cell Cycle Progression (2021) (0)
Acute megakaryoblastic leukaemia in Down syndrome and non-Down syndrome patients - molecular signature of a disease - subtypes with distinct treatment outcomes (2007) (0)
MATURATION OF BLOOD CELLS AND THEIR EXAMINATION IN PERIPHERAL BLOOD AND BONE MARROW (2010) (0)
Mechanisms of Response and Resistance to AML Therapies. (2020) (0)
heterogeneity in congenital dyserythropoietic anemia type I gene reveals genetic CDAN1 Linkage and mutational analysis of the (2011) (0)
T cell receptor V beta spectratyping using RT-PCR to monitor reconstitution following T cell depleted allogeneic BMT and the effect of donor leukocyte infusions on T cell repertoire. (1997) (0)
High expression of HMGA2 independently predicts poor clinical outcomes in acute myeloid leukemia (2018) (0)
De LibrisDe LibrisPathology and genetics: tumours of haematopoietic and lymphoid tissues, Elaine S Jaffe, Nancy L Harris, Harald Stein, James W Vardiman (Eds.), Oxford University Press (2001), £53, pp 351, ISBN: 9283224116 (2001) (0)
Single-Cell Analysis of Human Clonal Hematopoiesis Identifies Distinct Impact of DNMT3A and TET2 mutations on Hematopoietic Differentiation (2022) (0)
The bHLH protein SCL/Tal-l interacts with the co-repressor ETO-2 in erythroid cells and megakaryocytes. (2005) (0)
Graft Versus Leukaemia (GvL): Identification & Characterisation of Alloreactive Antigens and Cognate T Cell Responses in Acute Myeloid Leukemia (2022) (0)
MYELOMA AND RELATED CONDITIONS (2010) (0)
Characterisation and comparison of the human and mouse GATA-1 transcriptional domain. (2003) (0)
Bone marrow transplantation. (1990) (0)
FACTORS DETERMINING CLINICAL RESPONSE TO 5 '-AZACITDINE AND SODIUM VALPROATE COMBINATION THERAPY IN PATIENTS WITH HIGH RISK ACUTE MYELOID LEUKAEMIA AND MYELODYSPLASIA (2010) (0)
Identification of critical residues for the function of the bHLH transcription factor SCL in hematopoietic stem cells. (2003) (0)
S113 GENETICS AND MODELING OF HUMAN ACUTE ERYTHROID LEUKEMIA (2019) (0)
NON-HODGKIN LYMPHOMAS: MATURE B-CELL NEOPLASMS (2010) (0)
A Randomized Comparison of the Fractionated Versus Single Dose Schedule of Gemtuzumab Ozogamicin at Induction with Determinants of Benefit for Older AML Patients: UK NCRI AML18 Trial Results (2022) (0)
Functional and Genetic Heterogeneity of Distinct Leukemic Stem Cell Populations in CD34-Human Acute Myeloid Leukemia (2014) (0)
Interim Results from Clevo: A Non-Interventional Cohort Study Investigating the Clonal Evolution of FMS-like Tyrosine Kinase 3 (FLT3) Mutations during Disease Progression in Patients with Acute Myeloid Leukemia (2022) (0)
Supplementary file 6. (2014) (0)
SCL establishes a transcriptional and epigenetic repressive environment in blood-fated cells to suppress alternative mesodermal lineages (2016) (0)
Structure of the SCL:E47:LMO2:LDB1 complex bound to DNA (2013) (0)
Azacitidine Prolongs Overall Survival in Older Patients with Acute Myeloid Leukemia (AML) with Poor Prognostic Karyotypes (2017) (0)
Impact of Mutant Haemopoietic Transcription Factor GATA1s on Haemopoiesis (2017) (0)
BONE MARROW HAEMATOPOIESIS IN THE SECOND TRIMESTER OF FETAL LIFE IS STRONGLY BIASED TOWARDS B-LYMPHOPOIESIS AND IS SEVERELY IMPAIRED AT THE EBP-CBP TRANSITION IN DOWN SYNDROME (2010) (0)
AML-262 Pivekimab Sunirine (PVEK, IMGN632) Triplet With Azacitidine and Venetoclax Shows Broad Activity in Adverse Genetic Subsets of Relapsed/Refractory Acute Myeloid Leukemia and Reduced Infusion-Related Reactions. (2022) (0)
Shall We Dance: Evolving Partnerships of Targeted Therapies for AML. (2022) (0)
Poster: AML-399 A Phase 2, Open-Label, Multiarm, Multicenter Study to Evaluate Magrolimab Combined With Antileukemia Therapies for First-Line, Relapsed/Refractory, or Maintenance Treatment of Acute Myeloid Leukemia (AML) (2022) (0)
Lineage-specific transcriptional regulation of GATA1 is dependent on lineage-specific utilisation of multiple cis-elements and haematopoietic transcription factors. (2004) (0)
Dissecting human haematopoietic progenitors (2013) (0)
COMPREHENSIVE ANALYSIS OF MUTATION STATUS, GENE EXPRESSION PROFILES, BLOOD AND BONE MARROW COUNTS AND OUTCOME IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES (2014) (0)
Early identification of Patients with Primary Refractory Acute Myeloid Leukaemia who Benefit from Allogeneic stem cell transplantation: an analysis of 8,907 patients from the uk ncrn aml working group (2016) (0)
Myelodysplastic and Myeloproliferative Diseases in Children: Current Concepts (2014) (0)
Regulation of Gata1 Expression by HS + 3.5 (2010) (0)
Cross-Talk between c-Myb and GATA-1 Regulates the Entry into Megakaryocyte Differentiation. (2007) (0)
CLONAL STRUCTURES OF LEUKAEMIA STEM CELL POPULATIONS IN MYELOID BLAST PHASE CHRONIC MYELOID LEUKAEMIA (2016) (0)
AML-207: Glasdegib in Combination with Azacitidine in Patients with Untreated Higher-Risk Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia: Effects on Marrow Recovery and Transfusion Independence (2020) (0)
Abstract 634: Mutation agnostic diagnosis of clonal hematopoiesis of indeterminate potential using fluctuating methylation clocks (2022) (0)
Phase Ib study of eltrombopag and azacitidine in patients with high‐risk myelodysplastic syndromes and related disorders (the ELASTIC study) (2022) (0)
Analysis of GATA-1 mutations in chronic myeloid leukaemia. (2006) (0)
University of An operational definition of primary refractory acute myeloid leukemia allowing early identification of patients who may benefit from allogeneic stem cell transplantation (2017) (0)
Human Acute Myeloid Leukemia Clonal Evolution of Preleukemic Hematopoietic Stem Cells Precedes (2012) (0)
Therapy-Related Myeloid Neoplasms with Balanced Chromosome Rearrangements Frequently Arise from Pre-Existing Clonal Haematopoiesis (2018) (0)
BENIGN DISORDERS OF PHAGOCYTES (2018) (0)
Dysregulation of Stem-Progenitor and Differentiation Programmes through Modulation of Bivalent Chromatin Drives Leukemogenesis in Mutant IDH2 Acute Myeloid Leukaemia (2022) (0)
Poster: MDS-197: Magrolimab + Azacitidine Versus Azacitidine + Placebo in Untreated Higher-Risk (HR) Myelodysplastic Syndromes (MDS): The Phase 3, Randomized, ENHANCE Study (2021) (0)
myeloproliferative disorder and myeloid leukemia Analysis of GATA1 mutations in Down syndrome transient (2012) (0)
First-in-class, oral mutant IDH2 inhibitor reverses differentiation block in acute myeloid leukaemia to produce clinically meaningful responses (2017) (0)
Characterisation erythroid-specific cis-elements regulating the key transcription factor GATA1. (2006) (0)
Endoplasmic reticulum gene expression profile of erythroid progenitors in low risk myelodysplastic syndromes (2007) (0)
PS998 JANUS KINASE AND CYTOKINE RECEPTOR MUTATIONS IN TRANSIENT ABNORMAL MYELOPOIESIS AND MYELOID LEUKEMIA IN CHILDREN WITH TRISOMY 21 (2019) (0)
NIH consensus chronic GvHD following T-replete reduced-intensity conditioning sibling allograft usually develops within a year, causes prolonged morbidity but low mortality and is influenced by prophylactic methotrexate dose (2010) (0)
Activating CSF2RB Mutations Contribute to the Leukemic Transformation from TAM to ML-DS (2017) (0)
Molecular Features Associated with Response to Combination Therapy with Enasidenib (ENA) Plus Azacitidine (AZA) in Newly Diagnosed IDH2-Mutated Acute Myeloid Leukemia (AML) (2022) (0)
NGS IDENTIFIES MUTATIONS PROGNOSTIC OF RELAPSE AFTER ALLO-SCT AND NOVEL CLONE EMERGENCE AT DISEASE RECURRENCE: IMPLICATIONS FOR STRATEGIES TO PREVENT POST ALLO-SCT RELAPSE (2016) (0)
GENETIC DISORDERS OF HEMOGLOBIN (2010) (0)
Myeloid Pre-Leukemia and Leukemia of Down Syndrome (2020) (0)
Editing an α-globin enhancer in primary human hematopoietic stem cells as a treatment for β-thalassemia (2017) (0)
Type 1 inositol polyphosphate-4-phosphatase influences growth of primary megakaryocytes and other cell types and is differentially expressed in the absence of GATA-1. (1999) (0)
Oligonucleotide microarray analysis of CD34+cells in patients with low risk myelodysplasia and age-matched healthy subjects. (2003) (0)
Early PCR negativity in adults with t(4;11) acute lymphoblastic leukemia following allogeneic bone marrow transplantation. (1997) (0)
THE INHERITED AND ACQUIRED COAGULATION DISORDERS (2010) (0)
Dynamics of Clonal Hematopoiesis Inferred By Modelling Deep Bulk Whole-Genome Sequencing Data at a Single Time Point (2022) (0)
Molecular MRD Monitoring Is Feasible in the Majority of Children with AML and Is Highly Predictive of Outcome: Results from the International MyeChild01 Study (2019) (0)
Characterising the cell biology of leukemic stem cells in acute myeloid leukemia. (2013) (0)
APLASTIC AND DYSERYTHROPOIETIC ANEMIAS (2018) (0)
Supplementary file 5. (2014) (0)
AML-432 Overall Survival (OS) by IDH2 Mutant Allele (R140 or R172) in Patients With Late-Stage, Mutant-IDH2 Relapsed/Refractory Acute Myeloid Leukemia (AML) Treated With Enasidenib or Conventional Care Regimens (CCR) in the Randomized, Open-Label, Phase 3 IDHENTIFY Trial. (2022) (0)
Good news for the aging population? (2008) (0)
Abstract A019: Mutation agnostic diagnosis of clonal hematopoiesis of indeterminate potential (CHIP) using fluctuating methylation clocks (2022) (0)
Luspatercept significantly reduces red blood cell transfusion burden, regardless of gene mutation frequency, spectrum, and prognostic significance, among patients with lower-risk myelodysplastic syndromes enrolled in the MEDALIST trial (2020) (0)
Genotyping of Multiple Genomic Loci with Chromatin Accessibility Profiling in Single Cells Links Clonal Hierarchy with Epigenetic Variation in Acute Myeloid Leukemia (2022) (0)
Cellular and Molecular Basis of Mutant Haemopoietic Transcription Factor GATA1s (2014) (0)
Single Cell Characterisation of Transcriptional Programmes of Responsive and Resistant Leukaemic Progenitors in IDH2-Mutant Acute Myeloid Leukaemia in the AG221-AML-005 Study (2022) (0)
Shared care protocol for the management of essential thrombocythaemia patients in primary care (2011) (0)
P071 Endoplasmic reticulum gene expression profile of erythroid progenitors in low risk myelodysplastic syndromes (2007) (0)
Azacitidine: Duration of treatment used in routine clinical practice in patients with myelodysplastic syndromes (MDS) in England (2015) (0)
Author Correction: Patterns of somatic structural variation in human cancer genomes (2020) (0)
The mechanism of Nov (CCN3) function in haematopoiesis (2012) (0)
Genetic and Transcript Changesin Cereblon in IMiD-Treated Myeloma Patients (2019) (0)
Characterisation of SCL DNA-binding functions in vivo in haematopoiesis. (2005) (0)
Characterization of distinct GATA-1 complexes in erythroid cells. (2005) (0)
PSY41 MEASUREMENT OF HEALTH UTILITY VALUES IN THE UK FOR HEALTH STATES RELATED TO IMMUNE (IDIOPATHIC) THROMBOCYTOPENIC PURPURA (ITP) (2009) (0)
BENIGN DISORDERS OF LYMPHOCYTES (2010) (0)
Most haematological abnormalities in neonates with Down syndrome are transient but dysplastic myelopoiesis persists throughout early childhood (2019) (0)
THE PORPHYRIAS AND IRON OVERLOAD (2018) (0)
Stem cells deficient in p21Cip1/Waf1 compete poorly in establishing long-term bone marrow hematopoiesis. (2003) (0)
A Novel Model of Human Hemopoiesis Based on Single Cell Functional and Transcriptional Analysis of Lympho-Myeloid Progenitors (2017) (0)
Magrolimab in Combination With Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes: Final Results of a Phase Ib Study. (2023) (0)
Cellular and molecular basis of haematopoiesis (2020) (0)
TISSUE TYPING AND STEM CELL TRANSPLANTATION (2010) (0)
A tubulin binding molecule drives differentiation of acute myeloid leukemia cells (2022) (0)
Mature Analysis of the Prospective Oxford Down Syndrome (DS) Cohort Study: Timing and Clinical Impact of Preleukemic GATA1 Mutations and Lessons for Management of Newborns with DS (2017) (0)
Single-cell analysis reveals the continuum of human lympho-myeloid progenitor cells (2017) (0)
Author Correction: Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples (2020) (0)
MDS-197: Magrolimab + Azacitidine Versus Azacitidine + Placebo in Untreated Higher-Risk (HR) Myelodysplastic Syndromes (MDS): The Phase 3, Randomized, ENHANCE Study (2021) (0)
10 YEARS EXPERIENCE OF TYROSINE KINASE INHIBITOR THERAPY FOR CML IN A SINGLE UK CENTRE: COMPARISON WITH PRE-TKI ERA AND EVALUATION OF 2013 ELN GUIDELINES (2014) (0)
Salvage chemotherapy and donor lymphocyte infusion induces durable remissions in AML relapsing following allogeneic stem cell transplantation (2018) (0)
Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib (2018) (0)
AML-399 A Phase 2, Open-Label, Multiarm, Multicenter Study to Evaluate Magrolimab Combined With Antileukemia Therapies for First-Line, Relapsed/Refractory, or Maintenance Treatment of Acute Myeloid Leukemia (AML). (2022) (0)
A systematic review of the prenatal diagnosis and management of transient abnormal myelopoiesis (2015) (0)
The oncoprotein SCL/Tal-1 associates with the co-repressor ETO-2 in multiprotein complexes in erythroid cells and megalkaryocytes. (2004) (0)
Correction: High expression of HMGA2 independently predicts poor clinical outcomes in acute myeloid leukemia (2019) (0)
murine megakaryopoiesis is critical for p21 SCL-mediated regulation of the cell-cycle regulator (2012) (0)
Correction: High expression of HMGA2 independently predicts poor clinical outcomes in acute myeloid leukemia (2019) (0)
homeostasis Haploinsufficiency of GATA-2 perturbs adult hematopoietic stem cell (2013) (0)
PERIPHERAL T-CELL DISORDERS (2010) (0)
Genetic and non-genetic mechanisms of inflammation may promote transformation in leukemia. (2022) (0)
A Phase 1b Study of Eltrombopag and Azacitidine in Patients with High Risk Myelodysplastic Syndromes and Related Disorders (2020) (0)
DOT1L inhibition reveals a distinct subset of enhancers dependent on H3K79 methylation (2019) (0)
Nature of Clinical Response and Depth of Molecular Response in Patients with TP53 Mutant Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Treated with Magrolimab with Azacitidine (2022) (0)
Development of Therapeutic Antibodies Targeting Human Acute Myeloid Leukemia Stem Cells (2019) (0)
Enigmatic variation. (2011) (0)
Myelodysplastic syndrome due to somatic GATA1 mutation. (2004) (0)
stem cell transplantation in patients with acute myeloid leukemia (AML) Azacitidine augments expansion of regulatory T cells after allogeneic (2012) (0)
A simple and direct method to define clonal selection in somatic mosaicism (2021) (0)
SCL/TAL1 cooperates with Polycomb RYBP-PRC1 to suppress alternative lineages in blood-fated cells (2018) (0)
MDS-482 Impact Of Magrolimab in Combination With Azacitidine on Red Blood Cells (RBCs) in Patients With Higher-Risk Myelodysplastic Syndromes (HR MDS). (2022) (0)
Identification and Preliminary Structure-Activity Relationship Studies of 1,5-Dihydrobenzo[e][1,4]oxazepin-2(3H)-ones That Induce Differentiation of Acute Myeloid Leukemia Cells In Vitro (2021) (0)
Early PCR-negativity after allogeneic BMT in adults with t(4;11) ALL in the absence of acute or chronic GVHD (1999) (0)
Clinical and Hematologic Impact of Fetal and Perinatal Variables on Mutant GATA1 Clone Size in Neonates with Down Syndrome (2014) (0)
GTAC enables parallel genotyping of multiple genomic loci with chromatin accessibility profiling in single cells. (2023) (0)
JAK mutations in Down syndrome-associated transient myeloproliferative disorder and acute megakaryocytic leukemia. Authors' reply (2008) (0)
187 Combined sodium valproate and 5-azacitidine in the treatment of myelodysplastic syndrome (2011) (0)
Assessment of longer-term efficacy, safety, and haematological improvement in the phase 3, randomised, double-blind, placebo-controlled MEDALIST trial of luspatercept to treat anaemia in patients with lower-risk myelodysplastic syndromes with ring sideroblasts who require red blood cell transfusions (2020) (0)
SECONDARY ANEMIA AND BONE MARROW IN NONHEMATOPOIETIC DISORDERS (2010) (0)
Heterogeneous genetic and non‐genetic mechanisms contribute to response and resistance to azacitidine monotherapy (2022) (0)
Enasidenib in mutant relapsed or refractory acute myeloid leukemia. (2017) (0)
Structure of the SCL:E47 complex bound to DNA (2013) (0)
Bivalent chromatin modification (2013) (0)
with Down syndrome: identification of a population at risk of leukemia -mutant clones are frequent and often unsuspected in babies GATA1 (2013) (0)
Combining Clinical Features with Genetic Factors Improves Survival Prediction for Adults with Acute Myeloid Leukemia: Validation of a New Score System in 3 Cohorts (2019) (0)
Co-Existence of LMPP-Like and GMP-Like Leukemia Stem Cells In Acute Myeloid Leukemia (2010) (0)
Single cell assays unveil functional and transcriptional heterogeneity of human hemopoietic lympho-myeloid progenitors (2017) (0)
Health-Related Quality of Life (HRQoL) during Treatment with Enasidenib (ENA) Plus Azacitidine (AZA) in Patients with Newly Diagnosed Mutant IDH2 (m IDH2) Acute Myeloid Leukemia (AML) Not Eligible for Intensive Chemotherapy (IC) (2021) (0)
Erratum to Myelodysplastic syndromes are propagated by rare and distinct human cancer stem cells in vivo, [Cancer Cell, 25, 2014, 794-808] (2014) (0)
GATA1 mutational analysis in chronic myeloid leukaemia (2007) (0)
Cancer stem cells (2019) (0)
Classic and overlap chronic graft-versus-host disease after T-replete reduced intensity conditioned sibling allograft usually starts within a year, causes prolonged morbidity but low mortality and is influenced by prophylactic methotrexate and ciclosporin dosing (2010) (0)
CHRONIC MYELOID (MYELOGENOUS) LEUKEMIAS AND MYELODYSPLASTC/MYELOPROLIFERATIVE NEOPLASMS (2010) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Paresh Vyas?

Paresh Vyas is affiliated with the following schools:

Paresh Vyas's Academic­Influence.com Rankings

Paresh Vyas's Degrees

Similar Degrees You Can Earn

Why Is Paresh Vyas Influential?

Paresh Vyas's Published Works

Published Works

What Schools Are Affiliated With Paresh Vyas?

Paresh Vyas's AcademicInfluence.com Rankings